Table 1.
Properties of the human breast cancer cell lines subjected to treatment.
| SK-BR-3 | HCC1419 | MDA-MB-231 | MDA-MB-468 | |
|---|---|---|---|---|
| Subtype [28,29] | Luminal Subtype | Luminal Subtype | Basal B Subtype | Basal A Subtype |
| Source [28] | Pleural Effusion | Primary Tumor | Pleural Effusion | Pleural Effusion |
| Tumor Type [28] | Adenocarcinoma | Ductal Carcinoma | Metastatic Adenocarcinoma | Metastatic Adenocarcinoma |
| Estrogen Receptor [28,29,30] | - | - | - | - |
| Progesterone Receptor [28,29,30] | - | - | - | - |
| EGFR * [30] | +2 | - | +1 | +3 |
| HER-2 * [28,29,30] | +3 | +1 | - | - |
| HER-3 * [8,29,31] | Moderate | Moderate/High | Low/Absent | Moderate |
| Ras Mutant [32,33] | Wild Type | Wild Type | mut-K | Wild Type |
* EGFR (Epidermal Growth Factor Receptor), HER-2 (Human Epidermal Growth Factor Receptor-2), HER-3 (Human Epidermal Growth Factor Receptor-3).